Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Study of Tepotinib Effect on Midazolam in Healthy Subjects
NCT03628339Phase 1Completed
- Sponsor
- Merck KGaA
- Start
- Aug 2018
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of tepotinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Merck KGaA. Primary endpoints: Area Under Plasma Concentration-time Curve From Time Zero to Last Sampling Time (Tlast), Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity and 1 more. Started Aug 2018; status: completed.
02
Drugs
tepotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03628339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03628339.